Gyre Therapeutics is buying Cullgen in an all‑stock deal valued at approximately $300 million, aiming to close in the...

Codexis reported fourth-quarter 2025 revenue of $38.9 million and full-year revenue of $70.4 million, buoyed by a $37.8 million...

Tenaya Therapeutics outlined a 2026 cadence aimed at moving two cardiac gene therapies toward pivotal-readiness while extending its cash...

Pliant Therapeutics has initiated a Phase 1b indication expansion trial for PLN-101095, an oral dual inhibitor of αvβ8 and...

Chris Boshoff's public pivot toward oncology and obesity signals more than a pipeline refresh at Pfizer. Three converging moves...

Evaxion has delivered a 2025 reset built on external validation and extended runway. The techbio vaccine developer reported full-year...

Aquestive Therapeutics will resubmit the U.S. NDA for Anaphylm, its sublingual epinephrine film for severe allergic reactions, in the...

ARS Pharmaceuticals reported $72.2 million in U.S. net product revenue for neffy, its FDA- and EC-approved intranasal epinephrine, in...

Santhera has appointed Marc Clausse as Chief Commercial Officer, effective June 1, 2026, succeeding Geert Jan van Daal, who...

Enzon Pharmaceuticals has extended the deadline for its exchange offer to convert Series C non-convertible redeemable preferred stock into...